WallStSmart

Abbott Laboratories (ABT)vsUniversal Health Services Inc (UHS)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Abbott Laboratories generates 155% more annual revenue ($44.33B vs $17.36B). ABT leads profitability with a 14.7% profit margin vs 8.6%. UHS appears more attractively valued with a PEG of 1.29. UHS earns a higher WallStSmart Score of 76/100 (B+).

ABT

Buy

51

out of 100

Grade: C-

Growth: 5.3Profit: 6.5Value: 7.3Quality: 4.8
Piotroski: 3/9

UHS

Strong Buy

76

out of 100

Grade: B+

Growth: 7.3Profit: 7.0Value: 10.0Quality: 7.5
Piotroski: 6/9Altman Z: 2.97
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

ABTSignificantly Overvalued (-315.5%)

Margin of Safety

-315.5%

Fair Value

$25.23

Current Price

$104.83

$79.60 premium

UndervaluedFair: $25.23Overvalued
UHSUndervalued (+78.6%)

Margin of Safety

+78.6%

Fair Value

$1081.08

Current Price

$186.72

$894.36 discount

UndervaluedFair: $1081.08Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

ABT3 strengths · Avg: 8.3/10
Market CapQuality
$180.82B9/10

Large-cap with strong market position

Operating MarginProfitability
21.6%8/10

Strong operational efficiency at 21.6%

Free Cash FlowQuality
$2.63B8/10

Generating 2.6B in free cash flow

UHS4 strengths · Avg: 8.8/10
P/E RatioValuation
8.1x10/10

Attractively priced relative to earnings

Return on EquityProfitability
21.3%9/10

Every $100 of equity generates 21 in profit

Price/BookValuation
1.6x8/10

Reasonable price relative to book value

EPS GrowthGrowth
42.7%8/10

Earnings expanding 42.7% YoY

Areas to Watch

ABT4 concerns · Avg: 3.8/10
PEG RatioValuation
1.524/10

Expensive relative to growth rate

P/E RatioValuation
28.1x4/10

Moderate valuation

Revenue GrowthGrowth
4.4%4/10

4.4% revenue growth

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

UHS0 concerns · Avg: 0/10

No major concerns identified

Comparative Analysis Report

WallStSmart Research

Bull Case : ABT

The strongest argument for ABT centers on Market Cap, Operating Margin, Free Cash Flow.

Bull Case : UHS

The strongest argument for UHS centers on P/E Ratio, Return on Equity, Price/Book. PEG of 1.29 suggests the stock is reasonably priced for its growth.

Bear Case : ABT

The primary concerns for ABT are PEG Ratio, P/E Ratio, Revenue Growth.

Bear Case : UHS

No major red flags identified for UHS, but monitor valuation.

Key Dynamics to Monitor

UHS carries more volatility with a beta of 1.26 — expect wider price swings.

UHS is growing revenue faster at 9.1% — sustainability is the question.

ABT generates stronger free cash flow (2.6B), providing more financial flexibility.

Monitor MEDICAL DEVICES industry trends, competitive dynamics, and regulatory changes.

Bottom Line

UHS scores higher overall (76/100 vs 51/100). Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Abbott Laboratories

HEALTHCARE · MEDICAL DEVICES · USA

Abbott Laboratories is an American multinational medical devices and health care company with headquarters in Abbott Park, Illinois, United States. The company was founded by Chicago physician Wallace Calvin Abbott in 1888 to formulate known drugs; today, it sells medical devices, diagnostics, branded generic medicines and nutritional products. It split off its research-based pharmaceuticals business into AbbVie in 2013.

Visit Website →

Universal Health Services Inc

HEALTHCARE · MEDICAL CARE FACILITIES · USA

UnitedHealth Group Incorporated is an American for-profit multinational managed healthcare and insurance company based in Minnetonka, Minnesota. It offers health care products and insurance services.

Visit Website →

Want to dig deeper into these stocks?